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Researchers in the Molecular Cardiology and Angiogenesis Laboratory have found that damaged diabetic hearts can be repaired using combination gene therapy.   
 Nilanjana Maulik, Ph.D., professor in the Department of 
Surgery, found in preclinical studies that adenoviral VEGF 
(vascular endothelial growth factor) and Ang-1 (angiopoietin-1) 
increased blood flow and the heart’s ability to pump more 
effectively. The study is published in Diabetes, a journal of the 
American Diabetes Association.   
 “In diabetes, there is impairment of myocardial angiogenesis – 
decreased vessel formation in the heart which leads to decreased 
blood flow and eventually to heart failure,” explains Maulik. The 
decrease in blood vessel formation is mainly due to the imbalance 
in growth factors such as VEGF and Ang-1. 
 Scientists have long studied ways in which gene therapy could 
be used to repair the damaged diabetic heart. Most of the studies 
have focused on using a single gene as the therapeutic agent. 
Maulik decided to focus on a combination gene therapy which 
proved to be the key.  
 In animal studies, diabetic hearts damaged by myocardial 
infarctions were injected with a mixture of VEGF and Ang-1.  
Thirty days later, heart function was measured using an 
echocardiogram. The hearts subjected to this therapy performed 
better than the untreated hearts. “We observed reduced fibrosis 
and increased capillary and arteriolar density in the treated 
diabetic hearts compared to the diabetic hearts that were not 
treated with the combination therapy,” explains Maulik. The next 
step is a clinical trial to test the therapy’s effectiveness in humans 
with diabetic heart failure. n 
out that even though spores may be genetically identical…
they don’t all behave identically,” says Setlow. During 
germination, spore number one may come back to life in 
5 minutes but spores two, three and four may take their 
time and not germinate for 30 minutes, 24 hours or up 
to a month. Setlow says that’s where the problem arises. 
For example, if you’re being treated for anthrax, how long 
should you take antibiotics – for a week? Then the spore 






Setlow believes if his team can figure out why there is 
this heterogeneity - why one spore germinates faster than 
another - they might be able to figure out a way to get the 
spores to all germinate at the same time. An instrument 
developed by Ji Yu, Ph.D., in the Center for Cell Analysis 
and Modeling is crucial to this research. Instead of studying 
whole spore populations, Yu’s apparatus will allow them to 
look at one spore at a time, how it germinates differently 
from other spores and perhaps how it differs from other 
spores in the population. 
 “If we can better understand this process, maybe we can 
figure out ways to subvert it, figure out a better way to kill 
the spores,” adds Setlow. “Then there would be big savings 
in terms of food quality, energy costs, etc., and medical 
treatments for bacterial diseases could be more effective and 
potentially life-saving.” n
Bacterial spores can be nasty.  Just ask Peter Setlow, Ph.D., a professor in the Department of Molecular, Microbial and Structural 
Biology, who has been studying them for over 
40 years. He’ll tell you that spores, such as those 
of Bacillus anthracis, can cause anthrax. Other  
bacterial spores are to blame for deadly cases of 
food poisoning, botulism, and life-threatening 
infections that are especially hazardous to hospitalized patients. 
Setlow heads a team of researchers who have been awarded a 
multimillion dollar grant from the Department of Defense to 
uncover some of the secrets of spores and potentially make them 
less dangerous. 
 “The vegetative organisms cause the disease but it’s the spores 
that transmit the disease,” explains Setlow. “When they are 
dormant, they’re very resistant and can survive all kinds of harsh 
chemical treatments, extremes of temperature and low-nutrient 
environments. However, once the spores germinate, they are easy 
Talk about progress: a massive effort that took 10 years to complete 
just a decade ago can now be 
accomplished in a matter of 
days. I’m talking about the 
sequencing of RNA expression 
and the speed and precision of 
“next generation” technologies 
like our powerhouse, the 
Illumina® Genome Analyzer. As 
you will see in our lead story, 
next generation technologies 
recently helped researchers 
publish two major papers in 
RNA and Cell. 
This is a source of great pride for 
the UConn School of Medicine 
and a powerful reminder of how 
fortunate we are to be educators 
during a time of such profound 
growth and discovery.  
 Every day, the momentum 
and energy of our school, our 
students and our faculty is felt 
in Connecticut and beyond. 
In this issue, you will also 
learn about achievements of 
our faculty across a broad 
range of medical specialties 
from angiogenesis and gene 
therapy to novel approaches to 
prevent high blood pressure and 
advocacy for cancer survivors.  
 As always, please do not 
hesitate to share your thoughts 
about medical education with 
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to kill. Our research goal is to better understand the mechanisms 
that spur them to come out of their dormant phase and spring 
back to life.” 
 The award is for $1.25 million per year for a total of five years 
and is a Multidisciplinary University Research Initiative (MURI) 
grant designed to support basic science and/or engineering 
research at U.S. institutions of higher education that are of 
critical importance to national defense.  
 Along with focusing on the mechanisms of spore germination, 
Setlow and his team are studying their heterogeneity. “It turns 
Grants
Health Center Researcher  
Awarded Multimillion Dollar  
Department of Defense Grant
Peter Setlow, professor in the Department of Molecular, Microbial and Structural Biology
Research
Vitamin D is known to be important to bone health, but what about heart health? UConn Health Center physician-scientists are looking into a possible link between vitamin D deficiency and high blood pressure. 
 “Often patients don’t realize they have a vitamin D deficiency, or are unaware 
of its relationship with health problems other than bone disorders,” says the 
study’s principal investigator William B. White, M.D., professor of medicine and 
hypertension expert in the Pat and Jim Calhoun Cardiology Center.  
 White and Pooja Luthra, M.D., assistant professor of medicine and an 
endocrinologist in the New England Musculoskeletal Institute, are recruiting 
patients with a diagnosis of treated or untreated high blood pressure and a low 
vitamin D level. 
 In the 14-week, double-blind, randomized trial, participants will receive either vitamin D supplements or an enzyme blocker that 
targets renin, which is produced in the kidney. They then will get both medications in combination. Their blood pressure will be 
monitored both in the office setting and out of the office using a 24-hour ambulatory blood pressure monitor. 
 The UConn Health Center study is supported by an independent $480,000 investigator-initiated grant from Novartis 
Pharmaceuticals, Inc., in East Hanover, N.J., over the next three years. n 
Momentum Is Strong
“ It turns out that even though spores may  
 be genetically identical...they don’t all  
 behave identically.”  
v
William B. White, M.D., and Pooja Luthra, M.D.
Vitamin D Low, Blood Pressure High?
Health Center Researchers Find Combination 
Gene Therapy Effective in Healing Hearts
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At first glance it appears to be just another laboratory slide, a millimeter-thick rectangle 1.5 centimeters wide by 6.5 centimeters long. But when it’s examined against 
a light source, a series of whispery parallel lines 
becomes apparent. They are internal walls that 
separate the slide into eight chambers each of 
which is as narrow as angel hair pasta.  
 When Brenton Graveley, Ph.D., associate 
professor of genetics and developmental 
biology, inserts the slide into a squat device 
called a cluster station, clear liquid is 
injected through the almost imperceptibly 
small holes at the ends of the chambers. The 
slide is instantaneously transformed into a 
library of information. The liquid injected into 
the eight tiny chambers contains samples of genetic 
material, chemically extracted from organic tissue. And 
with the help of the Health Center’s powerful Illumina® Genome 
Analyzer, Graveley will soon know the precise sequence of 
genes in each sample. 
 
“Soon” is the key word. In the Health Center’s Translational 
Genomics Core, a center that provides a host of esoteric 
services for monitoring gene and microRNA expression, the 
sequencer is both a workhorse and a thoroughbred, 
a brute for work and incredibly fast. While 
sequencing technology has been around for 
almost a quarter of a century, “next generation 
sequencers” like this one are emphatically 
21st century. To understand how rapidly – 
and dramatically – they have revolutionized 
genetic research, it is worth considering 
how they would have impacted the Human 
Genome Project. 
 Launched in 1990, when Graveley was 
still a graduate student, that celebrated research 
program occupied an army of researchers worldwide 
who spent a full decade determining the sequence of 
chemical base pairs that make up human DNA. For the record, 
there are about three billion base pairs containing the 20,000 
to 25,000 distinct genes that make up the 23-chromosome 
human genome.  
Next-Generation Sequencer
The project resulted in a working draft of the genome in 2000 
and a more complete draft three years later. At that point, next 
generation sequencers were still a couple years in the future 
and, as the adage goes, timing is everything. “Our sequencer can 
process more than twice the number of bases in the genome,” 
says Graveley, matter-of-factly, “in about five days.” In fact, armed 
with the Illumina sequencer, which the Health Center acquired 
in the spring of 2008, Graveley’s team has already generated 
over 125 billion bases of sequence, more than 40 times the size 
of the human genome. And, he notes, “The output is increasing 
exponentially.”  
 Some of those data are included in two papers co-authored 
by Graveley and recently accepted for publication in the 
prominent journals RNA and Cell. The RNA paper is about 
a family of small RNAs that are expressed in planarians 
(flatworms) and required for the worms’ well-known ability to 
regenerate and for their stem cells to function. The Cell paper 
focuses on small RNAs in bacteria that function to defend the 
bacteria against invading viruses. They are the first two papers 
containing data generated by the Illumina sequencer. But they 
are only the vanguard. 
 
The Mysteries of Alternative Splicing
Part of what has made the new sequencers so popular are 
scientific breakthroughs in the study of microRNAs and 
alternative splicing that have significantly changed the research 
picture in the nine years since the Human Genome Project 
was completed. “As recently as the late 1990s, it was thought 
that most human genes encoded only a single messenger 
RNA (mRNA) isoform,” says Graveley. “Now we know that 
alternative splicing is the rule, not the exception. In fact, 95 
percent of human genes encode at least two isoforms and most 
known alternative-splicing events are regulated.” 
 Graveley and his team are currently hard at work on one 
line of related research. They are one of six teams at major 
universities all over the U.S. participating in a project called 
modENCODE, funded by the National Human Genome 
Research Institute, part of the National Institutes of Health. 
Researchers in the modENCODE project are trying to identify 
the myriad alternative splicing pathways in the genomes 
of Drosophila melanogaster, the common fruit fly, and 
Caenorhabditis elegans, a tiny roundworm. The project is less 
about those organisms than it is about the process of unraveling 
the mysteries of their sequence-based functional elements. 
 Graveley’s team is working on the fruit fly, an insect that has 
captivated his scientific imagination for years. “The Drosophila’s 
genome is very compact and only about one-tenth the size of 
the human genome,” he says. “That makes it very useful for this 
research.” 
 Even so, completing the project – which involves studying 
which genes are turned on and off at some 30 points over the 
course of the fly’s short, two to three week lifespan – is expected 
to take about four years, so complex are the twists and turns of 
the fly’s genetic sequencing. Graveley’s team is about halfway 
through. “When the project is complete, researchers expect to 
know much more about how to tackle studying the much more 
complex human genome. That task is expected to be wrapped 
up by 2012.” n
    Winter 2010UConn School of Medicine
Brenton Graveley, Ph.D.,  
associate professor  




Dental Researchers Study Potential Treatment 
for Common Chemotherapy Side Effect 
Douglas Peterson, D.M.D., Ph.D., is leading a team of researchers who are studying treatments to prevent oral mucositis in patients undergoing high-dose cancer therapy. 
Peterson is a professor of oral medicine in the Department of 
Oral Health and Diagnostic Sciences in the School of Dental 
Medicine and is also the chair of the Head and Neck/Oral 
Oncology Program in the Neag Comprehensive Cancer Center. 
Peterson and his team authored a paper that was recently 
published in the Journal of Clinical Oncology. The study evaluated 
the safety and efficacy of a topical oral spray for the prevention 
and treatment of chemotherapy-induced oral mucositis. 
      Oncology patients may 
develop mouth problems during 
and following cancer treatment, 
including painful mouth ulcers, 
infection, taste changes and/or 
dryness. Relative to the clinical 
trial, a sore, ulcerated mouth is a 
frequent side effect of high-dose 
chemotherapy and/or head and 
neck radiation. The mouth, as well 
as the remainder of the digestive 
tract, contains lining cells (mucosa) 
that are sensitive to several types of cancer therapies. Injury to 
these lining cells in the mouth results in oral mucositis, which 
can appear as redness (inflammation) and sores (ulcerations). The 
condition can lead to pain that may cause hospitalization and/or 
cancer treatment interruptions if sufficiently severe.  
 In the phase II, randomized, double-blind, placebo-
controlled study, Peterson and his colleagues tested an oral spray 
containing recombinant human intestinal trefoil factor (rhITF) 
administered for approximately two weeks during the period 
of highest risk development of oral mucositis. They found the 
spray to be safe and highly effective when used for the reduction 
of chemotherapy-associated oral mucositis in patients with 
colorectal cancer. Future clinical study is planned to develop 
this drug for use in oral mucositis management in patients 
undergoing high-dose cancer therapies. n 
471 Number of scientists 
actively involved in biomedical 




At first glance it appears to be just another laboratory slide, a millimeter-thick rectangle 1.5 centimeters wide by 6.5 centimeters long. But when it’s examined against 
a light source, a series of whispery parallel lines 
becomes apparent. They are internal walls that 
separate the slide into eight chambers each of 
which is as narrow as angel hair pasta.  
 When Brenton Graveley, Ph.D., associate 
professor of genetics and developmental 
biology, inserts the slide into a squat device 
called a cluster station, clear liquid is 
injected through the almost imperceptibly 
small holes at the ends of the chambers. The 
slide is instantaneously transformed into a 
library of information. The liquid injected into 
the eight tiny chambers contains samples of genetic 
material, chemically extracted from organic tissue. And 
with the help of the Health Center’s powerful Illumina® Genome 
Analyzer, Graveley will soon know the precise sequence of 
genes in each sample. 
 
“Soon” is the key word. In the Health Center’s Translational 
Genomics Core, a center that provides a host of esoteric 
services for monitoring gene and microRNA expression, the 
sequencer is both a workhorse and a thoroughbred, 
a brute for work and incredibly fast. While 
sequencing technology has been around for 
almost a quarter of a century, “next generation 
sequencers” like this one are emphatically 
21st century. To understand how rapidly – 
and dramatically – they have revolutionized 
genetic research, it is worth considering 
how they would have impacted the Human 
Genome Project. 
 Launched in 1990, when Graveley was 
still a graduate student, that celebrated research 
program occupied an army of researchers worldwide 
who spent a full decade determining the sequence of 
chemical base pairs that make up human DNA. For the record, 
there are about three billion base pairs containing the 20,000 
to 25,000 distinct genes that make up the 23-chromosome 
human genome.  
Next-Generation Sequencer
The project resulted in a working draft of the genome in 2000 
and a more complete draft three years later. At that point, next 
generation sequencers were still a couple years in the future 
and, as the adage goes, timing is everything. “Our sequencer can 
process more than twice the number of bases in the genome,” 
says Graveley, matter-of-factly, “in about five days.” In fact, armed 
with the Illumina sequencer, which the Health Center acquired 
in the spring of 2008, Graveley’s team has already generated 
over 125 billion bases of sequence, more than 40 times the size 
of the human genome. And, he notes, “The output is increasing 
exponentially.”  
 Some of those data are included in two papers co-authored 
by Graveley and recently accepted for publication in the 
prominent journals RNA and Cell. The RNA paper is about 
a family of small RNAs that are expressed in planarians 
(flatworms) and required for the worms’ well-known ability to 
regenerate and for their stem cells to function. The Cell paper 
focuses on small RNAs in bacteria that function to defend the 
bacteria against invading viruses. They are the first two papers 
containing data generated by the Illumina sequencer. But they 
are only the vanguard. 
 
The Mysteries of Alternative Splicing
Part of what has made the new sequencers so popular are 
scientific breakthroughs in the study of microRNAs and 
alternative splicing that have significantly changed the research 
picture in the nine years since the Human Genome Project 
was completed. “As recently as the late 1990s, it was thought 
that most human genes encoded only a single messenger 
RNA (mRNA) isoform,” says Graveley. “Now we know that 
alternative splicing is the rule, not the exception. In fact, 95 
percent of human genes encode at least two isoforms and most 
known alternative-splicing events are regulated.” 
 Graveley and his team are currently hard at work on one 
line of related research. They are one of six teams at major 
universities all over the U.S. participating in a project called 
modENCODE, funded by the National Human Genome 
Research Institute, part of the National Institutes of Health. 
Researchers in the modENCODE project are trying to identify 
the myriad alternative splicing pathways in the genomes 
of Drosophila melanogaster, the common fruit fly, and 
Caenorhabditis elegans, a tiny roundworm. The project is less 
about those organisms than it is about the process of unraveling 
the mysteries of their sequence-based functional elements. 
 Graveley’s team is working on the fruit fly, an insect that has 
captivated his scientific imagination for years. “The Drosophila’s 
genome is very compact and only about one-tenth the size of 
the human genome,” he says. “That makes it very useful for this 
research.” 
 Even so, completing the project – which involves studying 
which genes are turned on and off at some 30 points over the 
course of the fly’s short, two to three week lifespan – is expected 
to take about four years, so complex are the twists and turns of 
the fly’s genetic sequencing. Graveley’s team is about halfway 
through. “When the project is complete, researchers expect to 
know much more about how to tackle studying the much more 
complex human genome. That task is expected to be wrapped 
up by 2012.” n
    Winter 2010UConn School of Medicine
Brenton Graveley, Ph.D.,  
associate professor  




Dental Researchers Study Potential Treatment 
for Common Chemotherapy Side Effect 
Douglas Peterson, D.M.D., Ph.D., is leading a team of researchers who are studying treatments to prevent oral mucositis in patients undergoing high-dose cancer therapy. 
Peterson is a professor of oral medicine in the Department of 
Oral Health and Diagnostic Sciences in the School of Dental 
Medicine and is also the chair of the Head and Neck/Oral 
Oncology Program in the Neag Comprehensive Cancer Center. 
Peterson and his team authored a paper that was recently 
published in the Journal of Clinical Oncology. The study evaluated 
the safety and efficacy of a topical oral spray for the prevention 
and treatment of chemotherapy-induced oral mucositis. 
      Oncology patients may 
develop mouth problems during 
and following cancer treatment, 
including painful mouth ulcers, 
infection, taste changes and/or 
dryness. Relative to the clinical 
trial, a sore, ulcerated mouth is a 
frequent side effect of high-dose 
chemotherapy and/or head and 
neck radiation. The mouth, as well 
as the remainder of the digestive 
tract, contains lining cells (mucosa) 
that are sensitive to several types of cancer therapies. Injury to 
these lining cells in the mouth results in oral mucositis, which 
can appear as redness (inflammation) and sores (ulcerations). The 
condition can lead to pain that may cause hospitalization and/or 
cancer treatment interruptions if sufficiently severe.  
 In the phase II, randomized, double-blind, placebo-
controlled study, Peterson and his colleagues tested an oral spray 
containing recombinant human intestinal trefoil factor (rhITF) 
administered for approximately two weeks during the period 
of highest risk development of oral mucositis. They found the 
spray to be safe and highly effective when used for the reduction 
of chemotherapy-associated oral mucositis in patients with 
colorectal cancer. Future clinical study is planned to develop 
this drug for use in oral mucositis management in patients 
undergoing high-dose cancer therapies. n 
471 Number of scientists 
actively involved in biomedical 





Philip P. Smith, M.D., head of the Center for Continence and Voiding 
Disorders is the recipient of 
a Dennis W. Jahnigen Career 
Development Scholars Award 
from the American Geriatrics 
Society. 
 The Jahnigen Career 
Development Scholars Awards 
Program provides two-year grants of $200,000, including 
an institutional match, to assist young faculty as they initiate 
and ultimately sustain a career in research and education in 
the geriatrics aspects of their discipline. Smith is the only 
2009 Jahnigen scholar from Connecticut and one of seven 
nationwide. The grant will support his research in the area of 
lower urinary tract function in old age under the mentorship  
of Peter Albertsen, M.D., chief of the UConn Division of 
Urology, and George A. Kuchel, M.D., director of the UConn 
Center on Aging. 
 An abstract of Smith’s winning proposal is available at 
http://www.americangeriatrics.org/hartford/2009_Jahnigen_
Career_Development_Scholars.shtml#smith. n
Mentoring, Mother’s Professional 
Influence Leads to Laurencin’s  
Lifetime of Success 
His career has taken him to the forefront of musculoskeletal care and research, recognition by the White House, national prominence in his field, and the helm of the 
UConn Health Center as the vice president for health affairs. 
However, the inspiration that started Cato T. Laurencin, M.D., 
Ph.D., down the road of medicine was provided by his mother, 
who operated a clinical practice and research laboratory on the 
first floor of the family’s row house in North Philadelphia. 
 It is in her name and honor that Laurencin and his wife, 
Cynthia, have now created a fellowship for UConn School 
of Medicine students. The Helen I. Moorehead-Laurencin, 
M.D. Research Fellowship Fund supports students who have 
demonstrated academic achievement and are involved in 
conducting summer research projects. He says the emphasis 
on research perfectly matches his mother’s passion for 
understanding the science of medicine. 
 The fellowship addresses the other area of focus of 
Moorehead-Laurencin’s life: ensuring that young people have 
a mentor. Recipients must provide mentorship to an inner city 
high school student in the Hartford region. Laurencin says 
that his mother sought out and assisted young people in their 
neighborhood, encouraged them to pursue careers in medicine 
and science, and counseled those around her. 
 In addition to contributing a major gift to create the fund, 
Laurencin will also utilize an additional $10,000 presented to 
him as a recipient of the 2009 Presidential Awards for 
Excellence for supporting student research experiences. n
Located in a new, larger facility, and fresh from recruiting a new research expert through the support of private giving, the Department of Dermatology is also celebrating two major gifts. 
 A pledge of $100,000 from Jane M. Grant-Kels, M.D., chair 
of the department, and her husband, Barry D. Kels, J.D., M.D., 
executive director of risk management has been matched dollar-
for-dollar by an anonymous donor, a grateful patient of Grant-Kels. 
 “The support shown by Jane and Barry, as well as our grateful 
patients at the Health Center, is a testament to the generosity and 
commitment of those most personally connected to the UConn 
Health Center,” says Cato T. Laurencin, M.D., Ph.D., vice president 
for health affairs.  
 The gifts are part of an upcoming sustained fundraising effort 
for the department, which includes the preliminary goal of a 
$3-million distinguished endowed department head chair in 
melanoma and cutaneous oncology or psoriasis. 
 In addition, the department recently recruited a leading 
researcher to the cutaneous oncology program, partially supported 
through funds raised by the (2007) Imagine gala.
 Soheil Sam Dadras, M.D., Ph.D., a specialist in cutaneous 
melanoma, has joined the research team at the Health Center. 
Grant-Kels says that his addition shows the power that private 
giving can have in elevating research efforts at the University. n
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Honors Gifts
Dr. Faryal Mirza Recognized for  
Osteoporosis Research
T he American Society for Bone and Mineral Research has presented the 2009 ASBMR 
Award for Most Outstanding 
Research in the Pathophysiology 
of Osteoporosis to Faryal Mirza, 
M.D., an endocrinologist with the 
New England Musculoskeletal 
Institute. 
    Mirza was recognized for  
her abstract of her study on the 
role of sclerostin, a hormone 
believed to inhibit bone 
formation, in the development of postmenopausal osteoporosis. n
Cato T. Laurencin, M.D., Ph.D., in his research lab with a group of scientists for 
whom he serves as mentor
Carolyn D. Runowicz, M.D., Director of the Neag Comprehensive 
Cancer Center continues 
to be a national voice for 
a range of cancer-related 
issues, from increased 
awareness about cancer 
survivorship to advocacy 
for more robust activity in 
clinical research. 
       Since 2004, she has 
served on the National 
Cancer Advisory Board 
(NCAB), and has held the role of chair since 2006. She is the 
first gynecologic oncologist to hold this position. The role of 
the NCAB is to advise the secretary of the U.S. Department of 
Health and Human Services and the Director of the National 
Cancer Institute with regard to its activities, including the 
review and recommendation of support grants and cooperative 
agreements. There are 18 members of the advisory board 
which include leading representatives from health and science 
disciplines; all are appointed by the president of the U.S.  
 In addition, Runowicz also serves as Chair of the Clinical 
Research Committee for the American Society of Clinical 
Oncology (ASCO), the world leading professional organization 
representing physicians who treat people with cancer.  
 “Working with national organizations is a tremendous 
opportunity to help all of us achieve strategic objectives 
related to improvements in the prevention, early detection and 
treatment of cancers,” said Runowicz who previously served as 
President of the American Cancer Society. n
Advocating for Advances in  
Cancer Research and Care 
Jane M. Grant-Kels, M.D., chair of the Department of Dermatology
22 Years UConn medical students 
have been providing primary care 
and counseling to Hartford’s homeless 
at the South Park Inn Medical Clinic.
 
Fast Fact
Dr. Philip P. Smith  
Honored by American 
Geriatrics Society
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a Dennis W. Jahnigen Career 
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Center on Aging. 
 An abstract of Smith’s winning proposal is available at 
http://www.americangeriatrics.org/hartford/2009_Jahnigen_
Career_Development_Scholars.shtml#smith. n
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The University of Connecticut is establishing a center of innovation that 
will include its world-renowned Stem 
Cell Institute and Center for Cell Analysis 
and Modeling as well as cutting edge 
genetics and genomics research. The $52 
million, 117,000 sq. ft. Cell and Genome 
Sciences building will be equipped with 
the latest technologies for studying stem 
cells and their genomes. The new center 
will unite UConn scientists in a cross-
disciplinary, collaborative setting to enhance 
Connecticut’s role as a leader in biomedical 
research and accelerate discoveries that 
ultimately could lead to therapies treating 
a broad range of diseases and disorders. 
Situated on 24 acres of land near the Health 
Center campus, the renovation is expected 
to be completed by the summer of 2010. 
Coming Soon: 
A Center of Innovation
